Fortescue 4Q Iron-Ore Shipments Down 1% On Year; Annual Exports Hit Top End of Target
By Rhiannon Hoyle
Fortescue Metals on Thursday said full-year iron-ore shipments rose by 2%, despite a dip in fourth-quarter volumes, and forecast exports to rise in the year ahead.
The world's fourth-largest iron ore producer reported shipments of 48.9 million metric tons for the three months through June, taking total volumes for the fiscal year to 192.0 million tons. That was up from 189.0 million tons a year earlier and at the top end of the company's forecast for shipments between 187 million and 192 million tons.
Fortescue said it expects to ship between 192 million and 197 million tons of the steel ingredient in the year through June, 2024.
The miner runs a network of iron-ore mines in remote northwest Australia. The company earlier this year started production at a new site there called Iron Bridge.
Write to Rhiannon Hoyle at rhiannon.hoyle@wsj.com
(END) Dow Jones Newswires
July 26, 2023 19:47 ET (23:47 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
After Earnings, Is Tesla Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is GE Aerospace Stock a Buy, a Sell, or Fairly Valued?
-
3 Good Stocks to Buy with Your Tax Refund in 2024 (Or with Any Extra Money)
-
SoFi Earnings: Revenue Growth Slows on Lower Loan Growth and Higher Credit Costs
-
Tesla: Full Self-Driving Approval In China Supports Our View for Deliveries Growth In 2024
-
Philips Earnings: Firm Reaches $1.1 Billion Settlement Agreement
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track